INTS FY2029 EPS Increased by Brookline Capital Markets

Intensity Therapeutics Inc. (NASDAQ:INTS) – Equities research analysts at Brookline Capital Markets lifted their FY2029 EPS estimates for Intensity Therapeutics in a research note issued to investors on Friday, August 14th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings of $7.40 per share for the year, up from their prior estimate of $7.33. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($2.70) per share.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24).

Several other equities research analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Finally, Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.50.

Intensity Therapeutics Trading Up 4.8%

Shares of Intensity Therapeutics stock opened at $4.15 on Monday. The stock has a market cap of $13.53 million, a P/E ratio of -0.73 and a beta of 2.76. The stock’s 50 day simple moving average is $4.26 and its 200-day simple moving average is $5.48. Intensity Therapeutics has a 1-year low of $3.51 and a 1-year high of $43.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00.

Institutional Trading of Intensity Therapeutics

Several hedge funds have recently made changes to their positions in the company. Legacy Advisors LLC acquired a new stake in shares of Intensity Therapeutics during the 4th quarter worth approximately $63,000. Mesirow Financial Investment Management Inc. grew its position in Intensity Therapeutics by 25.5% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after acquiring an additional 51,000 shares during the period. Geode Capital Management LLC grew its position in Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after acquiring an additional 201,357 shares during the period. Jane Street Group LLC purchased a new position in Intensity Therapeutics in the fourth quarter worth approximately $26,000. Finally, State Street Corp increased its stake in Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares during the last quarter. Hedge funds and other institutional investors own 3.74% of the company’s stock.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.